comparemela.com

Latest Breaking News On - Grünenthal group - Page 1 : comparemela.com

BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics

/PRNewswire/ BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern Health, a virtual chronic pain management program, today.

United statesFabia kehrenBrad lawsonGabriel baertschiAaron ganiWebmd health servicesFern healthMassachusetts generalMetrohealth systemPain neuroscience educationLatin americaGrünenthal group

Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration

/PRNewswire/ Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151,.

United statesAsia pacificMasashi miyamotoGabriel baertschiJeremy morganVenture collaboration for kyowa kirin internationalKyowa kirin internationalKyowa kirin co ltdJoint venture collaborationKyowa kirinChief executive officerNorth americaKirin internationalLatin americaGrünenthal group

Grünenthal s resiniferatoxin receives Breakthrough Therapy Designation from U S FDA for pain associated with osteoarthritis of the knee

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. Grünenthal is running.

United statesNordrhein westfalenSouth africaChristopher jansenJan adamsFlorian dieckmannGrunenthal groupEuropean unionNational institute of arthritisDrug administration breakthrough therapy designationRoute of administration parenteralDrug administrationBreakthrough therapy designationChief scientific officerTransient receptor potential vanilloidLatin america

Grünenthal closes deal to acquire testosterone therapy Nebido™ from Bayer for €495 million

/PRNewswire/ Grünenthal today announced the successful completion of its acquisition of NebidoTM from Bayer for €495 million. "Testosterone deficiency.

Nordrhein westfalenUnited statesFabia kehrenGabriel baertschiFlorian dieckmannGrunenthal groupLatin americanClinical endocrinologyLatin americaGrünenthal group

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million

/PRNewswire/ Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal s investigational medicine.

South africaUnited statesGabriel baertschiFlorian dieckmannChristopher jansenShionogi co ltdNational institute of arthritisRoute of administration parenteralChief executive officerTransient receptor potential vanilloidLatin americaGlobal burdenDisease studyAndmarkets reportOsteoarthritis therapeutics marketDrug type

vimarsana © 2020. All Rights Reserved.